Leading supplier of high-quality Metformin

Weifa commands around 8 percent of the global market for metformin, an active ingredient in first-line treatment of diabetes II.

We serve more than 30 leading pharmaceutical companies. Our present strongholds are Japanese and European customers with high quality requirements, and with export to USA.

Weifa produces Metformin at a dedicated modern plant in Kragerø, Norway – the world’s largest production line for Metformin. In a strictly controlled process, Metformin is synthesised and processed to provide among the purest and best free-flowing qualities in the market. To meet different customer requirements, the plant produces Metformin in different forms:

Metformin HCl
Direct compressible granulate (DC)
Tablets (250 mg, 500 mg, 850 mg and 1000 mg)

Current capacity is 3000 MT/year, but the plant is prepared for upgrade to 6000 MT.

See here for Metformin HCl spesifications.